BTC Capital Management Inc., an investment firm, has acquired a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the second quarter of this year, as stated in its recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund reportedly acquired 5,305 shares of Lantheus’ stock, which is estimated to be worth around $442,000.
As of September 19th, 2023, it is noteworthy to analyze the latest stock analysis on Lantheus. The medical equipment provider released its earnings results on Thursday, August 3rd. In this report, Lantheus announced an impressive earnings per share (EPS) of $1.40 for the quarter. This surpassed analysts’ consensus estimates by $0.17 per share.
Additionally, Lantheus exhibited a return on equity (ROE) of 67.18%, indicating strong profitability relative to shareholders’ investments. Furthermore, the company’s net margin was recorded at 2.97%, reflecting the percentage of revenue retained as profit after expenses are deducted.
During the specified quarter, Lantheus generated robust revenue of $321.70 million compared to analyst estimates of $306.48 million – surpassing expectations once again.
Sell-side analysts predict that Lantheus Holdings will achieve an EPS of 5.19 for the current fiscal year.
Considering BTC Capital Management Inc.’s recent acquisition and the consistently positive performance demonstrated in its earnings report, investors may find it worthwhile to closely monitor developments within Lantheus Holdings. As always, conducting comprehensive research and consulting with financial experts is advised before making any investment decisions relating to Nasdaq-listed stocks such as LNTH.
Target Corporation
TGT
Strong Buy
Updated on: 30/09/2023
Financial Health
Very Healthy
Debt to equity ratio: Strong Buy
Price to earnings ratio: Strong Buy
Price to book ratio: Strong Buy
DCF: Strong Buy
ROE: Neutral
Lantheus Holdings, Inc.: Growing Interest from Hedge Funds and Analysts
September 19, 2023 – The recent activities of hedge funds and other institutional investors have brought attention to Lantheus Holdings, Inc. (LNTH), a leading medical equipment provider. Hedge funds such as National Bank of Canada FI, AlphaMark Advisors LLC, and Macquarie Group Ltd. have all made significant moves in their positions within the company.
During the first quarter of this year, National Bank of Canada FI increased its stake in Lantheus by an astonishing 35.7%. Following the purchase of an additional 117 shares during this period, National Bank now owns a total of 445 shares with a value amounting to $37,000. AlphaMark Advisors LLC also made a considerable move by boosting its holdings in Lantheus by a staggering 456.3% during the same quarter. With the acquisition of an extra 365 shares, AlphaMark Advisors now holds 445 shares with a total value of $37,000.
Coppell Advisory Solutions Corp., on the other hand, recently entered the fray as it purchased a new stake in Lantheus during the fourth quarter of last year. Valued at $48,000, this move highlights confidence in the company’s growth potential.
As for Macquarie Group Ltd., it saw fit to increase its holdings in Lantheus by an impressive 21.7% during the first quarter of this year. Following their purchase of an additional 108 shares, Macquarie Group now possesses 605 shares valued at $50,000.
Clearstead Advisors LLC joined these institutions by acquiring a new stake in Lantheus during the first quarter as well. This new holding is valued at $52,000.
Altogether, hedge funds and institutional investors currently own a whopping 99.06% of Lantheus’ stock – indicative of strong interest and confidence from industry players.
Lantheus has also caught the attention of research analysts, with several reports highlighting the company’s potential. Truist Financial reaffirmed its “buy” rating on Lantheus’ shares and set a target price of $125.00. StockNews.com initiated its coverage on the company and also assigned it a “buy” rating. Lastly, TheStreet upgraded Lantheus from a “c” rating to a “b-” rating.
Bloomberg.com data shows that out of six equities research analysts covering the stock, all have given it a “buy” rating. The average target price for Lantheus stands at $121.83.
In other news, President Paul Blanchfield made significant movements in the company by selling 1,500 shares of Lantheus’ stock in August. This transaction saw an average sale price of $65.19, totaling $97,785.00 in value. Following this sale, President Blanchfield now holds 90,475 shares valued at approximately $5,898,065.25.
Another insider, Daniel Niedzwiecki, also sold 4,297 shares of Lantheus’ stock in August at an average price of $67.93 per share – resulting in a total transaction value of $291,895.21. Following this sale, Niedzwiecki has direct ownership of 66,295 shares with an estimated value of $4,503,419.35.
Over the last 90 days alone, insiders have sold 19,315 shares of Lantheus’ company stock amounting to a value of $1,353,773 – equivalent to 1.50% of the total outstanding shares.
On Tuesday morning following these developments and transactions within the company and its institutional investors’ activities; shares of Lantheus opened at $64.10 after reaching its highest point at $100.85 within the past year.
With a market capitalization of $4.39 billion, Lantheus exhibits a price-to-earnings ratio of 156.34 and a beta value of 0.68 – indicating relatively low risk compared to the market average. The company’s 50-day moving average stands at $73.57, while the 200-day moving average is recorded at $81.84.
Lantheus Holdings, Inc., despite recent fluctuations in its stock, boasts impressive financial ratios such as a current ratio of 4.88 and a quick ratio of 4.55, demonstrating strong liquidity.
In conclusion, Lantheus Holdings, Inc. continues to be a subject of investment interest and research analysis due to its position in the medical equipment industry and recent movements among institutional investors. With favorable ratings from research analysts and consistent insider trading activity, Lantheus may prove to be an attractive opportunity for investors looking for long-term growth potential in the healthcare sector.
Discussion about this post